New York, May 24, 2026, 16:03 EDT
Tandem Diabetes Care closed down around 5% to $14.96 on Friday, ahead of the long Memorial Day weekend. The insulin-pump maker’s shares ended the session lower as Nasdaq will be closed through Monday.
Tandem shares had bounced going into the end of the week. The LSEG-based lookup had TNDM finishing at $13.53 on Monday, $15.76 on Thursday, then slipping to $14.96 at Friday’s close. That’s still a gain of roughly 10.6% from where it started, despite giving up ground late in the week.
The indexes were green. The S&P 500 was up 0.4% Friday and the Nasdaq Composite gained 0.2%. The S&P 500 finished its eighth straight winning week, according to the Associated Press. TNDM lagged, falling in a stronger market.
Tandem’s Q1 numbers show a stronger story than the stock chart. The San Diego-based company posted record pump shipments topping 29,000 and sales at $247.2 million, with a gross margin of 55%. The company kept its 2026 sales outlook at $1.065 billion to $1.085 billion. President and CEO John Sheridan said 2026 goals are “firmly in focus.” Management is looking for an adjusted EBITDA margin of 5% to 6%. Tandem Diabetes Care
Tandem’s shift is what has Wall Street talking, not just this quarter’s numbers. Benchmark’s Bruce Jackson started coverage at Hold, saying the company is going after an “ambitious strategy” as it changes up its U.S. and international sales channels. He said that transition “will not be without pain.” TipRanks
Tandem’s strategy depends on its U.S. pharmacy move and a pay-as-you-go reimbursement plan. This model lets revenue come in gradually, not at device sale. CFO Leigh Vosseller told analysts the pharmacy setup in 2026 was “a whole different world” compared to last year and said Tandem was “very convicted” it could get U.S. new starts growing again. Investing
Governance and management news hit last week. In a May 21 filing, shareholders approved an amended long-term incentive plan, which adds 3.26 million shares for issuance and makes charter changes. Another SEC filing said Chief Commercial Officer Mark Novara was terminated without cause as of May 18. Tandem said its strategy and targets for 2026 remain the same.
The risk for Tandem is easy to spot. Insulet and Medtronic are its main rivals in insulin delivery, and the company’s annual filing lays out threats from competitors, lower prices, reimbursement shifts, and supply snags. If pharmacies don’t buy as fast as hoped, or if infusion sets remain hard to get, Friday’s drop could signal trouble instead of just profit-taking.
Tandem has nothing on the calendar before the Goldman Sachs global healthcare conference June 8, according to its investor website. So it’s the tape’s move when trading resumes Tuesday. A calm session would preserve the rebound from May 18-22, but if sellers come back, the turnaround story goes back under pressure.
